CureGN: Glomerulonephropathy Network.

CureGN is a prospective, multicentre study funded under a grant from the NIH (National Institute of Health). The project is dedicated only to American centers. However, taking into account the problem with the recruitment of at least 2,400 patients with 4 types of primary glomerulonephritis, assumed at the outset, and on the basis of the recommendations of Columbia University, with which our clinic has been cooperating since 2011, NIH has agreed to join our center to this project. JUSTIFICATION It is estimated that approximately 10% of the world's population has various degrees of renal failure, defined on the basis of serum creatinine and / or GFR. It is known that in the so-called developed countries, among all types of glomerulopathy, IgA nephropathy (IgAN) is the most common ONE, while the most common causes of nephrotic syndrome are membranous nephropathy (MN), minimal lesion disease (MCD) and focal segmental glomerular enamel (FSGS). Many patients may not develop symptoms early in the development of these diseases, and the cause of their development is, in fact, unknown. As a consequence, there are no sensitive and specific diagnostic methods, and we do not know the prognostic factors on the basis of which we could precisely determine, for example, the probability of progression and development of chronic/end-stage renal failure. OBJECTIVE AND EXPECTED RESULTS OF THE PROJECT: The aim is to collect and analyze clinical data and research results obtained during the project on four primary glomerulonephritis, i.e. IgA nephropathy, focal segmental glomerulosclerosis, membranous nephropathy and minimal lesion disease. The integration of clinical trials with the results of basic research on such a large, multiethnic group of patients is to find sensitive and specific markers (e.g. genetic, proteomic) that will allow to describe the causes of the development and further course of these diseases. https://curegn.org/